New hope for kidney cancer patients whose disease returns after standard therapy

NCT ID NCT06863311

Recruiting now Disease control Sponsor: Karie Runcie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called zanzalintinib, either alone or with an immunotherapy (nivolumab), in people with advanced kidney cancer that got worse after standard adjuvant therapy. About 70 adults will take part. The goal is to see if the drug shrinks tumors and is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED RENAL CELL CARCINOMA CLEAR CELL RENAL CELL CARCINOMA METASTATIC RENAL CELL CARCINOMA

Contacts and locations

Locations

Columbia University Irving Medical Center
RECRUITING

New York, New York, 10032, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITING

Indianapolis, Indiana, 46202, United States
University of California San Diego
RECRUITING

La Jolla, California, 92093, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.